CoDon AG  

(Public, ETR:CNW)   Watch this stock  
Find more results for CNW
Delayed:   3:19PM GMT+2
ETR data delayed by 15 mins - Disclaimer
Currency in EUR
Range     -
52 week 0.50 - 1.40
Open     -
Vol. 0.00
Mkt cap 4.57M
P/E     -
Div/yield     -
EPS -0.24
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin -52.68% -88.42%
Operating margin -52.62% -88.41%
EBITD margin - -83.14%
Return on average assets -38.72% -58.42%
Return on average equity -50.99% -73.40%
Employees 56 -
CDP Score - -


Warthestr. 21
TELTOW, 14513
+49-3328-43460 (Phone)
+49-3328-434649 (Fax)

Website links


co don AG is a Germany-based company, which is active in the tissue engineering and regenerative medicine industry. The Company manufactures cell-based biological drugs for the use in orthopedic and neurosurgical applications. Its products are used for the treatment of focal particular cartilage defects, lumbar disc herniation, non-union fractures and dental disorders. Those include co don chondrotransplant, which is used for cartilage treatment, particularly in the knee area; co don chondrosphere, which is three-dimensional articular cartilage cultivated outside of the body; co don chondrotransplant DISC, for the regeneration of intervertebral discs, and co don osteotransplant DENT, which is an autologous bone cell transplant for dental applications. The Company is active domestically and in other European countries.

Officers and directors

Bernd Wegener Chairman of the Supervisory Board
Andreas Baltrusch Chairman of the Management Board, Chief Executive Officer
Thommy Staehlin Vice Chairman of the Supervisory Board
Vilma Methner Member of the Management Board, Chief Operating Officer, Chief Sales Officer
Thomas Krause Member of the Supervisory Board
Andrei Perov Member of the Supervisory Board
Stig Jarle Pettersen Member of the Supervisory Board
Age: 53
Barbara Sickmueller Member of the Supervisory Board